In 2021, the phase 2, single-arm MK-6482-004 trial reported that the HIF-2α inhibitor belzutifan had an ORR of 49% (95% CI 36-62) and showed activity in RCC and non-RCC tumors associated with VHL disease [75]. Here, EPAS1 is linked to renal cell carcinoma.